Navigation Links
New FDA Approved Drug NATRECOR For Heart Failure Patients

The US government has approved a genetically engineered drug called NATRECOR to ease the breathing of hospitalized congestive heart failure patients.

Congestive heart failure is a condition // in which the heart can't pump enough blood to meet the needs of the body's other organs. Most of the patients with congestive heart failure suffer flare-ups in which they gasp for breath and need hospitalization.

The U.S. Food and Drug Administration approved an injection of Natrecor as a way to treat these acute flare-ups. Natrecor, known chemically as nesiritide, is a biologically engineered version of a natural hormone that helps dilate blood vessels. That dilation helps blood flow from the weakened heart. But it also can cause seriously low blood pressure.

Two years ago, the FDA rejected approval of Natrecor because it caused so many cases of hypotension rates of 8 percent to 14 percent, depending on the dose used. Hence studies were conducted in another study group of 498 patients with a much smaller dose. This time, low blood pressure struck only about 4 percent of patients. So the FDA approved an injection containing the lower Natrecor dose.

Studies showed patients could breathe better as blood circulation and lung congestion improved with Natrecor treatment. California-based Scios Pharmaceuticals said it will start shipping Natrecor to hospitals this week and each vial, a day's treatment, will cost $380.


'"/>




Page: 1

Related medicine news :

1. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
2. New FDA Approved Drug To Treat Migraine
3. New Oral Rinse For Gingivitis Approved By FDA
4. Child Friendly Zidovudine Preparation for treating HIV infection Approved By The FDA
5. AIDS Generic Drugs Approved by FDA for Sale in US
6. FDA Approved Nerve-Stimulation Therapy Now Available In New York
7. Revlimid Approved For Treatment Of Myelodysplastic Syndrome (MDS) by FDA
8. Pfizer’s Eraxis Approved By The FD
9. Inhalers for Kids Was Approved By the FDA
10. Alcoholism Drug Vivitrol Approved By FDA
11. Drug Approved to Curb Alcohol Dependency
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and ... drug safety and minimize the cost of development. In this webinar, sponsored by ... cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , ...
(Date:4/28/2017)... ... ... Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published a ... does not. Yisrayl says with so many titles and names for the Creator, it’s ... with a little Scripture, backed with a lot of research, the truth is undeniable. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Intellitec Solutions announced the ... implement a Microsoft Dynamics GP solution that integrates to their PointClickCare EHR software ... in long-term care, Brooke Grove now has the capability to achieve its goal ...
(Date:4/28/2017)... ... ... Rob Lowe is a popular actor that has been in many different ... purpose as the host of the “Informed” series. The program focuses on many important ... series focuses on thyroid cancer. , Although thyroid cancer is an uncommon type of ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
(Date:4/19/2017)... DALLAS , April 19, 2017  Vanderbilt University ... first patients in Nashville , Tennesse ... Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. ... to provide long-term reflux control by restoring normal function ... nearly 65 million people in the United ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
Breaking Medicine Technology: